The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
Both recent FDA draft guidance and a new research framework encourage the use of biomarker diagnostics to assess Alzheimer's before symptoms emerge.
Quest will have a broader relationship with Cleveland Clinic in diagnostic development, the companies say.
The firm believes the IsoPSA technology is superior to competitors, but clinicians argue that a lack of comparative studies could hamper adoption of all these tests.
As part of the acquisition, Quest has formalized an R&D agreement with Cleveland Clinic to commercialize emerging innovations.
Hospitals are increasingly recognizing the impact that improper lab test ordering can have on costs and patient care, doctors said.
A national center of excellence in cardiometabolic disorders will be created, focused on diagnostic information services.
The levels of the metabolite could predict near- and long-term cardiovascular events or death, the research team reported.
The test uses the company's SIA platform, a protein biomarker technology that measures different protein isoform populations to assess patient disease states.